Vaubel Rachael A, Chen Selby G, Raleigh David R, Link Michael J, Chicoine Michael R, Barani Igor, Jenkins Sarah M, Aleff Patrice Abell, Rodriguez Fausto J, Burger Peter C, Dahiya Sonika, Perry Arie, Giannini Caterina
From the Department of Anatomic Pathology (RAV, CG), Mayo Clinic, Rochester Minnesota; Department of Neurosurgery (SGC), Mayo Clinic, Jacksonville, Florida; Department of Radiation Oncology (DRR, IB), University of California, San Francisco, California; Department of Neurosurgery (MJL), Mayo Clinic, Rochester Minnesota; Department of Neurologic Surgery (MRC), Washington University, St. Louis, Missouri; Departments of Biomedical Statistics and Informatics (SMJ), Mayo Clinic, Rochester Minnesota, Departments of Biochemistry and Molecular Biology (PAA), Mayo Clinic, Rochester Minnesota; Department of Pathology (FJR, PCB), Johns Hopkins University, Baltimore, Maryland; Departments of Pathology and Immunology/Anatomic and Molecular Pathology (SD), Washington University, St. Louis, Missouri; Department of Pathology (AP), University of California, San Francisco, California.
J Neuropathol Exp Neurol. 2016 Jan;75(1):44-52. doi: 10.1093/jnen/nlv006. Epub 2015 Dec 7.
The behavior of rhabdoid meningiomas otherwise lacking malignant features remains unknown as most of the originally reported aggressive cases showed anaplastic histologic features independently of rhabdoid phenotype. We studied 44 patients with rhabdoid meningiomas lacking anaplastic features. Median age at diagnosis was 48.6 years (range 10-79). Location was supratentorial in 28 (63.6%), skull base in 15 (34.1%), and spinal in 1 (2.3%). Tumor grade was otherwise World Health Organization grade I (n = 22, 50%) or II (n = 22, 50%). Rhabdoid cells represented <20% of the tumor in 12 cases (27.3%), 20% to 50% in 18 (40.9%), and >50% in 14 (31.8%). Median clinical follow-up, available for 38 patients, was 5.0 years (range 0.17-14.2). Recurrence occurred in 9 patients (5-year recurrence-free survival, 73.7%) with a significantly higher risk in subtotally resected tumors (p = 0.043). Rhabdoid cell percentage was not associated with recurrence. Six patients died (4 of disease, 2 of unclear causes); 5-year overall survival was 86.7%, a mortality in excess of that expected in grade I-II meningiomas but much lower than originally reported. Review of 50 similar previously reported cases confirmed our findings. We suggest that rhabdoid meningiomas be graded analogously to nonrhabdoid tumors, with caution that some may still behave aggressively and close follow-up is recommended.
横纹肌样脑膜瘤若缺乏恶性特征,其行为仍不明确,因为最初报道的大多数侵袭性病例显示出间变性组织学特征,与横纹肌样表型无关。我们研究了44例缺乏间变性特征的横纹肌样脑膜瘤患者。诊断时的中位年龄为48.6岁(范围10 - 79岁)。肿瘤位于幕上的有28例(63.6%),颅底的有15例(34.1%),脊髓的有1例(2.3%)。肿瘤分级在其他方面为世界卫生组织I级(n = 22,50%)或II级(n = 22,50%)。12例(27.3%)患者的横纹肌样细胞占肿瘤的比例<20%,18例(40.9%)患者的比例为20%至50%,14例(31.8%)患者的比例>50%。38例患者有可用的中位临床随访时间,为5.0年(范围0.17 - 14.2年)。9例患者出现复发(5年无复发生存率为73.7%),次全切除的肿瘤复发风险显著更高(p = 0.043)。横纹肌样细胞百分比与复发无关。6例患者死亡(4例死于疾病,2例死因不明);5年总生存率为86.7%,死亡率高于I - II级脑膜瘤预期,但远低于最初报道。对50例先前报道的类似病例的回顾证实了我们的发现。我们建议横纹肌样脑膜瘤应与非横纹肌样肿瘤类似进行分级,但要注意一些肿瘤可能仍具有侵袭性,建议密切随访。